Ian Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 22,468 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Monday, January 27th, Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $40.50, for a total value of $660,757.50.

Xenon Pharmaceuticals Price Performance

NASDAQ XENE opened at $40.00 on Wednesday. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The company has a market capitalization of $3.05 billion, a PE ratio of -14.18 and a beta of 1.20. The company has a fifty day moving average of $40.23 and a two-hundred day moving average of $40.82.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter last year, the company posted ($0.73) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current year.

Analyst Ratings Changes

XENE has been the topic of a number of recent research reports. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $56.00.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several large investors have recently bought and sold shares of XENE. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 641 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $101,000. nVerses Capital LLC acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter worth about $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 487 shares in the last quarter. Finally, KBC Group NV raised its holdings in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.